|
|
||||||||





*
Departments of Pediatrics and Medicine, University of Tennessee, Memphis, TN 38163; and
Research Service of the Veterans Administration Medical Center, Memphis, TN 38163
Immunization of susceptible strains of mice with type II collagen
(CII) elicits an autoimmune arthritis known as collagen-induced
arthritis (CIA). One analogue peptide of the immunodominant T cell
determinant, A9 (CII245270 (I260
A,
A261
B, F263
N)), was previously shown to
induce a profound suppression of CIA when coadministered at the time of
immunization with CII. In the present study, A9 peptide was
administered i.p., orally, intranasally, or i.v. 2 to 4 wk following
CII immunization. We found that arthritis was significantly suppressed
even when A9 was administered after disease was induced. To determine
the mechanism of action of A9, cytokine responses to A9 and wild-type
peptide A2 by CII-sensitized spleen cells were compared. An increase in
IL-4 and IL-10, but not in IFN-
, was found in A9 culture
supernatants. Additionally, cells obtained from A9-immunized mice
produced higher amounts of IL-4 and IL-10 when cultured with CII
compared with cells obtained from mice immunized with A2, which
produced predominantly IFN-
. Suppression of arthritis could be
transferred to naive mice using A9-immune splenocytes. Lastly,
phosphorylation of TCR
was not altered in the immunoprecipitates
from the lysates of cells exposed to analogue peptides (A9 and A10)
together with wild-type A2 in a T cell line and two
I-Aq-restricted, CII-specific T hybridomas. We conclude
that analogue peptide A9 is effective in suppressing established CIA by
inducing T cells to produce a Th2 cytokine pattern in response to
CII.
This article has been cited by other articles:
![]() |
J. C. Huang, M. Vestberg, A. Minguela, R. Holmdahl, and E. S. Ward Analysis of autoreactive T cells associated with murine collagen-induced arthritis using peptide-MHC multimers Int. Immunol., February 1, 2004; 16(2): 283 - 293. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |